We are happy and proud to announce the acquisition of Organix, a US-based provider of high-quality organic chemistry services. The company is dedicated to the discovery and preclinical stage of the drug-discovery value chain, with a focus on lipids and small molecules. Organix has 47 employees, the majority of which have a PhD in chemistry, and is based in Woburn, in the Boston, MA, area. Its revenue is mainly generated from the sale of specialized and complex organic chemistry research services to biopharma clients.
Symeres and Organix are highly complementary, and the combination unlocks significant strategic value. Organix represents a high-quality foothold into the US market, where Symeres already generates about 40% of its revenues. Furthermore, Organix broadens the Symeres drug-discovery offering into the fast-growing lipids market, addressing mRNA therapeutics and vaccines. Organix’s impressive client list includes some of the world’s leading biopharma companies, many based in the Boston biopharma community. Organix management will remain unchanged; the company is led by Dr. Anu Mahadevan, CEO, and Dr. Paul Blundell.
Symeres CEO Eelco Ebbers is very pleased to quickly integrate Organix into the Symeres group: “Organix is widely known as being highly innovative and an expert organic chemistry services provider that is able to solve complex projects for top-tier clients globally. Joining forces represents a fantastic opportunity for us to expand our drug-discovery-capability offering and provide an exceptional high-quality foothold into the US market.”
As the majority shareholder in Symeres, Keensight Capital has worked together with the management team of the two companies to facilitate this combination. Amit Karna, Partner at Keensight Capital, comments: “We are delighted to support Symeres in this exciting acquisition of Organix. We are certain that the resulting business will create a truly differentiated transatlantic offering for the biopharma industry, with significant expertise in molecule design, synthesis, and early-stage clinical manufacturing. Moreover, the scientific and cultural fit of the two organizations could not be more perfect, and we are excited to see what the management teams will achieve together.”
Read the full press release here.
Latest news
Symeres earns first SBTi approval as part of long-term sustainability journey
Symeres appoints Gabriella Gentile as Chief Operating Officer to drive transatlantic growth
Symeres announces acquisition of DGr Pharma
Symeres and Yoneda Labs use AI to optimize cross-coupling reactions
New production lines D1 and D2 at our Prague site
New NMR technology – meet “Maggie”
Symeres announces leadership evolution
Official opening of new Oncolines home, the Marie Curie Building at the Pivot Park in Oss, the Netherlands
New equipment at Exemplify
New 100 L vessels in Groningen
Organix: New facility
Innovative macrocycles as powerful Mcl-1 inhibitors
Oncolines unveils new state-of-the-art laboratories
Peter Molenveld assumes role as secretary of KNCV (Royal Netherlands Chemical Society)
Chiral chemistry: in the DNA of Symeres
π-facial selectivity in the Diels–Alder reaction of glucosamine-based chiral furans and maleimides
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities
Symeres acquires Exemplify BioPharma, further strengthening its strategic foothold in the US
Expansion of solid-state center of excellence
Introducing Petr Cermak: “Returning to Prague feels like coming back for the future.”
Expanding the toolbox: Resolving racemates
Symeres joins forces with Keensight Capital
Speak with our experts
Let’s discuss how Symeres can support the discovery and development of your next breakthrough